See more : British Land Company Plc (BTLCY) Income Statement Analysis – Financial Results
Complete financial analysis of Hikma Pharmaceuticals PLC (HKMPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hikma Pharmaceuticals PLC, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Grupo Lamosa, S.A.B. de C.V. (LAMOSA.MX) Income Statement Analysis – Financial Results
- Torslanda Property Investment AB (publ) (TORSAB.ST) Income Statement Analysis – Financial Results
- Happy Helper A/S (HAPPY.CO) Income Statement Analysis – Financial Results
- Tata Coffee Limited (TATACOFFEE.BO) Income Statement Analysis – Financial Results
- Capricorn Energy PLC (CRNZF) Income Statement Analysis – Financial Results
Hikma Pharmaceuticals PLC (HKMPF)
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.88B | 2.52B | 2.55B | 2.34B | 2.21B | 2.07B | 1.94B | 1.95B | 1.44B | 1.49B | 1.37B | 1.11B | 918.03M | 730.94M | 636.88M | 580.66M | 448.80M | 317.02M | 262.22M | 212.38M | 105.15M | 85.50M |
| Cost of Revenue | 1.47B | 1.28B | 1.25B | 1.14B | 1.06B | 1.02B | 969.00M | 964.00M | 622.00M | 638.00M | 601.00M | 607.60M | 522.68M | 373.59M | 332.46M | 324.17M | 227.26M | 158.49M | 126.42M | 103.94M | 51.57M | 40.58M |
| Gross Profit | 1.41B | 1.24B | 1.30B | 1.20B | 1.15B | 1.05B | 967.00M | 986.00M | 818.00M | 851.00M | 764.00M | 501.12M | 395.35M | 357.34M | 304.43M | 256.48M | 221.53M | 158.53M | 135.79M | 108.44M | 53.58M | 44.92M |
| Gross Profit Ratio | 48.94% | 49.19% | 50.96% | 51.30% | 52.02% | 50.72% | 49.95% | 50.56% | 56.81% | 57.15% | 55.97% | 45.20% | 43.07% | 48.89% | 47.80% | 44.17% | 49.36% | 50.01% | 51.79% | 51.06% | 50.96% | 52.54% |
| Research & Development | 149.00M | 144.00M | 143.00M | 137.00M | 150.00M | 147.00M | 115.00M | 150.00M | 36.00M | 55.00M | 39.00M | 34.02M | 31.22M | 23.61M | 16.84M | 22.17M | 19.34M | 18.29M | 16.51M | 9.67M | 4.13M | 3.01M |
| General & Administrative | 638.00M | 509.00M | 488.00M | 464.00M | 453.00M | 246.00M | 238.00M | 208.00M | 180.00M | 185.00M | 151.00M | 124.56M | -43.12M | -29.85M | -38.86M | -47.35M | -17.67M | -4.96M | -4.76M | -4.63M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 494.00M | 224.00M | 188.00M | 184.00M | 156.00M | 171.00M | 160.00M | 152.76M | 125.30M | 106.67M | 98.08M | 90.56M | 61.02M | 35.01M | 27.37M | 19.73M | 0.00 | 0.00 |
| SG&A | 638.00M | 509.00M | 488.00M | 464.00M | 494.00M | 470.00M | 426.00M | 392.00M | 336.00M | 356.00M | 311.00M | 277.32M | 82.17M | 76.83M | 59.23M | 43.21M | 43.35M | 30.05M | 22.61M | 15.10M | 0.00 | 0.00 |
| Other Expenses | 253.00M | 0.00 | 0.00 | 0.00 | -50.88M | -59.22M | -60.92M | -88.83M | -54.02M | 0.00 | 0.00 | -1.17M | 2.33M | 0.00 | 0.00 | 0.00 | 0.00 | 938.00K | 1.45M | 732.00K | 0.00 | 0.00 |
| Operating Expenses | 1.04B | 756.00M | 742.00M | 687.00M | 655.00M | 690.00M | 635.00M | 611.00M | 401.00M | 449.00M | 412.00M | 334.34M | 276.73M | 222.04M | 197.80M | 176.64M | 129.34M | 84.16M | 67.59M | 46.06M | 22.62M | 20.29M |
| Cost & Expenses | 2.51B | 2.04B | 1.99B | 1.83B | 1.71B | 1.71B | 1.60B | 1.58B | 1.02B | 1.09B | 1.01B | 941.95M | 799.41M | 595.63M | 530.26M | 500.81M | 356.60M | 242.65M | 194.02M | 150.00M | 74.19M | 60.87M |
| Interest Income | 7.00M | 3.00M | 30.00M | 47.00M | 67.00M | 3.00M | 2.00M | 12.00M | 3.00M | 4.00M | 2.00M | 1.27M | 468.00K | 346.00K | 514.00K | 817.00K | 2.03M | 5.26M | 1.56M | 326.00K | 290.00K | 117.00K |
| Interest Expense | 90.00M | 77.00M | 69.00M | 69.00M | 67.00M | 80.00M | 60.00M | 104.00M | 57.00M | 38.00M | 37.00M | 35.72M | 23.37M | 13.86M | 12.83M | 17.55M | 10.84M | 4.96M | 5.21M | 3.83M | 1.90M | 2.55M |
| Depreciation & Amortization | 195.60M | 186.55M | 164.15M | 143.91M | 121.49M | 104.11M | 142.86M | 102.57M | 73.00M | 72.00M | 75.00M | 58.39M | 47.00M | 38.43M | 34.15M | 33.12M | 23.43M | 13.80M | 10.33M | 6.77M | 3.06M | 4.89M |
| EBITDA | 572.47M | 485.00M | 735.00M | 796.28M | 685.36M | 435.55M | -570.38M | 350.74M | 484.00M | 472.00M | 426.00M | 226.15M | 164.19M | 165.38M | 141.10M | 114.47M | 117.32M | 94.35M | 79.70M | 70.01M | 34.64M | 28.71M |
| EBITDA Ratio | 19.91% | 27.81% | 28.79% | 27.85% | 29.86% | 23.38% | 81.35% | 27.33% | 33.61% | 31.70% | 31.21% | 20.40% | 17.89% | 23.73% | 22.15% | 19.61% | 26.26% | 29.78% | 31.20% | 32.97% | 32.91% | 33.58% |
| Operating Income | 367.00M | 282.00M | 582.00M | 579.00M | 493.00M | 371.00M | -747.00M | 302.00M | 381.00M | 402.00M | 352.00M | 166.77M | 118.69M | 135.10M | 107.29M | 80.68M | 92.40M | 75.25M | 69.21M | 62.72M | 30.99M | 22.46M |
| Operating Income Ratio | 12.77% | 11.20% | 22.80% | 24.73% | 22.34% | 17.92% | -38.58% | 15.49% | 26.46% | 27.00% | 25.79% | 15.04% | 12.93% | 18.48% | 16.85% | 13.89% | 20.59% | 23.74% | 26.39% | 29.53% | 29.47% | 26.27% |
| Total Other Income/Expenses | -86.00M | -49.00M | -38.00M | -21.00M | -2.00M | -78.00M | 9.00M | -92.00M | -63.00M | -40.00M | -54.00M | -35.00M | -24.80M | -14.11M | -12.51M | -16.65M | -8.61M | 348.60K | -4.80M | -3.70M | -1.32M | -3.37M |
| Income Before Tax | 281.00M | 233.00M | 544.00M | 558.00M | 491.00M | 293.00M | -738.00M | 210.00M | 318.00M | 362.00M | 298.00M | 132.04M | 93.89M | 120.98M | 94.79M | 64.03M | 83.79M | 75.60M | 64.41M | 59.02M | 29.67M | 19.10M |
| Income Before Tax Ratio | 9.77% | 9.26% | 21.31% | 23.84% | 22.25% | 14.15% | -38.12% | 10.77% | 22.08% | 24.31% | 21.83% | 11.91% | 10.23% | 16.55% | 14.88% | 11.03% | 18.67% | 23.85% | 24.56% | 27.79% | 28.22% | 22.33% |
| Income Tax Expense | 89.00M | 42.00M | 124.00M | 128.00M | 4.00M | 8.00M | 101.00M | 52.00M | 64.00M | 80.00M | 82.00M | 24.83M | 10.42M | 21.46M | 15.47M | 6.92M | 19.60M | 19.64M | 19.45M | 20.84M | 11.91M | 8.52M |
| Net Income | 190.00M | 188.00M | 421.00M | 431.00M | 486.00M | 282.00M | -843.00M | 155.00M | 252.00M | 278.00M | 212.00M | 100.00M | 80.11M | 98.85M | 77.68M | 57.12M | 62.58M | 54.52M | 43.87M | 37.46M | 17.59M | 10.50M |
| Net Income Ratio | 6.61% | 7.47% | 16.49% | 18.41% | 22.02% | 13.62% | -43.54% | 7.95% | 17.50% | 18.67% | 15.53% | 9.02% | 8.73% | 13.52% | 12.20% | 9.84% | 13.94% | 17.20% | 16.73% | 17.64% | 16.73% | 12.28% |
| EPS | 0.86 | 0.82 | 1.79 | 1.95 | 2.09 | 1.17 | -3.51 | 0.67 | 1.27 | 1.40 | 1.08 | 0.51 | 0.41 | 0.51 | 0.41 | 0.30 | 0.37 | 0.33 | 0.30 | 26.30 | 0.11 | 0.06 |
| EPS Diluted | 0.85 | 0.82 | 1.78 | 1.93 | 2.08 | 1.17 | -3.50 | 0.66 | 1.25 | 1.39 | 1.07 | 0.51 | 0.41 | 0.50 | 0.40 | 0.30 | 0.35 | 0.31 | 0.28 | 24.80 | 0.11 | 0.06 |
| Weighted Avg Shares Out | 220.86M | 224.00M | 231.00M | 236.00M | 242.00M | 241.00M | 240.00M | 233.00M | 199.00M | 198.00M | 197.00M | 196.35M | 194.14M | 192.30M | 189.76M | 187.88M | 169.22M | 167.28M | 154.86M | 166.54M | 166.54M | 166.54M |
| Weighted Avg Shares Out (Dil) | 222.37M | 225.00M | 233.00M | 238.00M | 243.00M | 242.00M | 241.00M | 234.00M | 201.00M | 200.00M | 198.00M | 198.30M | 197.77M | 196.86M | 193.73M | 193.17M | 176.85M | 175.92M | 154.86M | 166.54M | 166.54M | 166.54M |
Hikma Pharmaceuticals (HKMPF) Upgraded to Buy: Here's What You Should Know
Hikma Pharmaceuticals (HKMPF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Hikma Pharmaceuticals PLC (HKMPF) Q2 2024 Pre-Recorded Presentation Transcript
Hikma Pharmaceuticals PLC (OTCPK:HKMPF) Q2 2024 Pre-Recorded Presentation August 8, 2024 2:30 AM ET Company Participants Riad Mishlawi - CEO & Director Khalid Nabilsi - CFO Riad Mishlawi Thank you for joining our 2024 half year results presentation. I'm Riad...
Hikma Pharmaceuticals rallies following bullish first-half earnings
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares bounced 7.6% higher on Thursday following publication of its half-year financial report. “We had an excellent first half of the year.
U.K. Top 40 Quality Dividend Stocks: Summer 2024
Unfortunately, UK investors have had to suffer weak or negative capital gains in recent years to get those high yields. The good news is that the UK remains an attractive market for dividend investors. Don't forget that companies usually retain...
Hikma beefs up complex manufacturing skillset with Xellia assets
Hikma Pharmaceuticals has bought a raft of US injectable or finished dosage form (FDF) assets from Copenhagen-based Xellia Pharmaceuticals for US$135 million cash and US$50 million in potential milestones. A commercial portfolio and pipeline of differentiated products, a manufacturing facility in...
U.K. Top 40 Quality Dividend Stocks: Q2 2024
The list ranks stocks based on their market cap and dividend yield alone. What I am looking for is quality dividend stocks with long track records of progressive dividend growth, and while dividend yield is still important, it's a secondary...
Hikma Pharmaceuticals PLC (HKMPF) Q4 2023 Earnings Call Transcript
Hikma Pharmaceuticals PLC (HKMPF) Q4 2023 Earnings Call Transcript
Hikma divi boost sends stock 5% higher
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF)'s shares rose 5% in early trade on Thursday, buoyed by robust annual results that prompted the company to increase its dividend by nearly a third. The pharmaceutical group reported a 14% rise in full-year revenues to...
Hikma Pharma resolves US opioid litigation
Shares in Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) rose then fell into the red after it announced overnight that it has agreed a settlement to resolve its opioid-related claims in the US. Under the agreement in principle, the FTSE 100-listed generic drug maker...
Ad firm Publicis, drugmaker Hikma settle US opioid cases for $500 million
A division of French advertising company Publicis Groupe SA and drug company Hikma Pharmaceuticals have reached separate settlements worth a collective $500 million to resolve claims that they helped fuel the deadly U.S. opioid epidemic.
Source: https://incomestatements.info
Category: Stock Reports